CLASS II Drug recall · Reported 23 Feb 2022 · FDA Enforcement Report

Moxifloxacin Ophthalmic Solution, USP 5% w/v, Sterile recalled

Aurobindo Pharma USA is recalling Moxifloxacin Ophthalmic Solution, USP 5% w/v, Sterile, distributed nationwide in the US. The recall was initiated on 14 Jan 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: CMF210001, CMF210003, CMF210004, Exp 6/2023
NDC65862-840
UPC0365862840035
Quantity recalled115776 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0560-2022
FDA event ID
89423
Recalling firm
Aurobindo Pharma USA, East Windsor, NJ
Manufacturer
Aurobindo Pharma Limited
Classification
Class II
Status
Terminated
Recall initiated
14 Jan 2022
FDA classified
14 Feb 2022
Reported
23 Feb 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Eye Drops

Timeline

14 Jan 2022Recall initiated by company
14 Feb 2022Classified by FDA+31 days
23 Feb 2022Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Moxifloxacin Ophthalmic Solution, USP 0.5% w/v, 3 mL bottle, Sterile, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, Made in India, NDC 65862-840-03

Where it was distributed

USA Nationwide

Nationwide

Questions about this recall

Is Moxifloxacin Ophthalmic Solution, USP 5% w/v, Sterile recalled?

Yes. Aurobindo Pharma USA recalled Moxifloxacin Ophthalmic Solution, USP 5% w/v, Sterile on 14 Jan 2022. The recall is Class II and its status is Terminated. Recall number D-0560-2022.

Why was it recalled?

Failed Impurities/Degradation Specifications

Which lots are affected?

Lot#: CMF210001, CMF210003, CMF210004, Exp 6/2023

Where was it sold?

USA Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Aurobindo Pharma USA

All 58

Other Moxifloxacin recalls

All 5